Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Paradigm Biopharmaceuticals (PAR) granted Fast Track Designation by the US Food and Drug Administration (FDA) for its phase-three osteoarthritis development program The company’s planned phase-three clinical trial will investigate its pent...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is rocketing today, up 21.55% in early afternoon trading. Paradigm shares closed yesterday at $1.16 and are currently trading for $1.41. However, they climbed as high as $1.60 earl...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 7,449.9 points. Four ASX shares that are not letting that hold them back t...

Paradigm Biopharmaceuticals (ASX:PAR) has announced it has received regulatory and ethics approval from the UK regulator for a key late-stage clinical trial.

The US Patent Office (USTPO) has issued a final rejection notice for Paradigm Biopharmaceuticals' (ASX:PAR) key osteoarthritis patent application.

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIZ)) - Air New Zealand ((ART)) - Airtasker ((APX)) - Appen ((ALX)) - Atlas Arteria ((AIA)) - Auckland International Airport ((AMI)) - Aurelia Metals ((ACL)) - Australia...

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

ASX director buying activity was fairly spread out over the past fortnight, with larger share sales few and far between.   Resources directors However one director who bucked that trend was Equus Mining (ASX:EQE) chairman Mark Lochtenberg...

World Overnight SPI Overnight 7235.00 + 10.00 0.14% S&P ASX 200 7332.50 – 76.30 – 1.03% S&P500 4532.76 – 44.35 – 0.97% Nasdaq Comp 14340.26 – 166.64 – 1.15% DJIA 35028.65 – 339.82 – 0.96% S&P500 VIX 23.85 + 1.06 4....

World Overnight SPI Overnight 7249.00 – 66.00 – 0.90% S&P ASX 200 7408.80 – 8.50 – 0.11% S&P500 4577.11 – 85.74 – 1.84% Nasdaq Comp 14506.90 – 386.86 – 2.60% DJIA 35368.47 – 543.34 – 1.51% S&P500 VIX 23.09 + 3.90 2...

World Overnight SPI Overnight 7340.00 + 22.00 0.30% S&P ASX 200 7417.30 + 23.40 0.32% S&P500 4662.85 + 3.82 0.08% Nasdaq Comp 14893.75 + 86.94 0.59% DJIA 35911.81 – 201.81 – 0.56% S&P500 VIX 19.19 – 1.12 – 5.51%...

Highlights Clinuvel completes enrolment in its world-first study of stroke with afamelanotide as treatment for arterial ischaemic stroke (AIS) patients. All patients under consideration showed good tolerance to the treatment without an...

Paradigm Biopharmaceuticals (PAR) doses its first two subjects with Zilosul in its phase three clinical trial for pain associated with knee osteoarthritis (kOA) The study will evaluate the dose and treatment effect of injectable pentosan p...

The company hopes to address vast unmet need in osteoarthritis patients across the developed world, where an estimated 120 million people are expected to be afflicted with this painful disease by 2030.

US inflation data came in at historic highs overnight, rising by 7% year-on-year — the highest level since 1982. Core inflation also came in slightly above expectations at 5.5%, although the monthly pace of headline inflation growth slowed...

Paradigm Biopharmaceuticals (PAR) says it has received positive interim data from a phase 2 pilot study of pentosan polysulfate sodium (PPS) for the treatment of mucopolysaccharidosis type I (MPS-I) Paradigm’s study enrolled three patients...

PPS was well tolerated with no serious adverse events reported over a 24-week period and there were meaningful improvements in pain, function and activities of daily living while an overall improvement in quality of life was observed in all...

Paradigm Biopharmaceuticals (PAR) sees a shake up to its leadership board, with CEO Paul Rennie transitioning from Managing Director to a non-executive role as Chairman In the non-executive role, Paul Rennie will focus on the direction of...

The company has initiated a search for a new CEO with global pharma experience and has already identified a number of potential candidates.

Dr Christian Reiter’s "extensive knowledge base and experience with PPS will be great value to Paradigm’s R&D projects in developing new pipeline and second-generation products, as well as Paradigm’s OA and MPS programs," Paradigm CSO D...

World Overnight SPI Overnight 7456.00 + 9.00 0.12% S&P ASX 200 7452.20 – 4.70 – 0.06% S&P500 4701.70 + 4.17 0.09% Nasdaq Comp 15982.36 + 10.77 0.07% DJIA 36432.22 + 104.27 0.29% S&P500 VIX 17.22 + 0.74 4.49% US 1...

After conducting market research across four major global markets to determine the willingness of patients to pay for and doctors to prescribe Zilosul®, the company found broad approval for the treatment, suggesting an acceptable market pri...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

On Wednesday I looked at three ASX shares brokers have given buy ratings to this week. Unfortunately, not all shares are in favour with them right now. Three ASX shares that have just been given sell ratings by brokers are listed below. He...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.3% to 7,415.7 points. Four ASX shares that have failed to follow the market’s lead today are...

Local stocks posted a solid session on Wednesday ahead of this week’s main event on global markets later tonight — the US Fed’s latest policy decision. After plenty of forward guidance, the Fed is expected to formally announce the taper of...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,398.1 points. Four ASX shares that are climbing more than most today are listed below....

“The opening of the trial in the USA – the largest global pharmaceutical market, is a major milestone. This represents a substantial de-risking of the company's lead clinical program and is a testament to the company's expertise, commitment...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Paradigm Biopharmaceuticals (PAR) has had its investigational new drug application cleared to proceed with a phase three trial on knee osteoarthritis pain The US FDA has given Paradigm the green light for a study evaluating injectable pent...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt and is charging higher on Wednesday. At the time of writing, the biopharmaceutical company’s shares are up 30% to $2.69. Why is the Paradigm shar...

While you were watching the Melbourne Cup the ASX retreated, the RBA hinted an interest rate hike could be coming sooner than 2024, and a new IPO gained 165%. The ASX 200 closed at 7,324 points – 0.63% down from yesterday. The best sector w...

The ASX 200 rose 0.64% on the first trading day of the month. All sectors were in the green except financials – a sector dragged down by Westpac (ASX:WBC) following its results. The best sectors were consumer discretionaries, telcos and uti...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is up 1.85% at time of writing to $1.93 per share. That’s a lift of more than 5% from its low of $1.83 in early morning trade. Below, we take a look at what’s helping drive today’s...

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment The company submitted the changes to the Human Research Ethics Committee, which included the addition of a test site in...

The complete set of results, including confirmatory studies will be prepared for peer review and publishing. Paradigm has filed a patent for the treatment of ARDS with PPS.

Wall Street falls as IMF warns of inflation US stock markets fell for the third consecutive day, as the International Monetary Fund (IMF) cuts its global growth projection from 6.5% to 5.9%, and warned about inflation. The IMF told the BBC...

Paradigm Biopharmaceuticals (PAR) receives top-line results from a preclinical study investigating treatment for acute respiratory distress syndrome The study saw pentosan polysulfate sodium (PPS) administered to an influenza model of acut...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a solid gain. At the time of writing, the benchmark index is up 0.7% to 7,393.6 points. Four ASX shares that have failed to follow the market high...

The company is confident it will soon be undertaking its phase 3 PPS clinical trial in US osteoarthritis patients.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is sinking on Monday morning. At the time of writing, the biopharmaceutical company’s shares are down 8.5% to $1.92. Why is the Paradigm share price sinking? The Paradigm share pri...

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

“We are pleased to report that preparations to commence our Phase 3 clinical trial are progressing whilst we await the US FDA’s response, expected at the end of September,” says CEO.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the move this Friday. This comes after the biopharmaceutical company provided an update in regards to its upcoming clinical trial. At the time of writing, Paradigm’s shares a...

Wall Street rallies higher Confidence has returned to US markets, following the US Fed’s policy update on Wednesday night. All three US stock market benchmarks climbed overnight, with the Dow Jones rising by 1.48%, S&P 500 by 1.21%, and...

“These critical findings provide confidence in PPS as a potential world-first CHIKV therapy,” said Dr Lara Herrero.

World Overnight SPI Overnight (Jun) 7454.00 – 17.00 – 0.23% S&P ASX 200 7527.10 – 7.80 – 0.10% S&P500 4524.09 + 1.41 0.03% Nasdaq Comp 15309.38 + 50.15 0.33% DJIA 35312.53 – 48.20 – 0.14% S&P500 VIX 16.11 – 0.37 –...

World Overnight SPI Overnight (Jun) 7444.00 – 33.00 – 0.44% S&P ASX 200 7534.90 + 30.40 0.41% S&P500 4522.68 – 6.11 – 0.13% Nasdaq Comp 15259.24 – 6.65 – 0.04% DJIA 35360.73 – 39.11 – 0.11% S&P500 VIX 16.48 + 0.29...